Grant AgreementGrant Agreement • April 11th, 2024
Contract Type FiledApril 11th, 2024The primary purpose of The Amyloidosis Foundation (the ”AF”) in funding scientifically meritorious research is to advance its mission to eradicate Systemic Amyloidosis as a life-threatening disease. The policies are provided to assist applicants and grantees in understanding the terms and conditions that apply to each Grant. The full terms and conditions applicable to each Grant are set forth in this Grant Agreement, which incorporates these policies. By accepting an AF grant or fellowship, the Sponsoring Institution agrees to the terms and conditions of this Policy and accepts full responsibility for the conduct of the investigation and the acts of the investigator; project personnel, compensated in full or in part with funds awarded by the AF, are employees of the Sponsoring Institution; they are not AF employees. The Grant term is from January 1 – December 31, 2025.
AMYLOIDOSIS FOUNDATIONGrant Agreement • April 13th, 2023
Contract Type FiledApril 13th, 2023The primary purpose of The Amyloidosis Foundation (the “AF”) in funding scientifically meritorious research is to advance its mission to eradicate Systemic Amyloidosis as a life threatening disease. The policies are provided to assist applicants and grantees in understanding the terms and conditions that apply to each Grant. The full terms and conditions applicable to each Grant are set forth in this Grant Agreement, which incorporates these policies. By accepting a AF grant or fellowship, the Sponsoring Institution agrees to the terms and conditions of this Policy and accepts full responsibility for the conduct of the investigation and for the acts of the investigator; project personnel, compensated in full or in part with funds awarded by the AF, are employees of the Sponsoring Institution; they are not AF employees. Grant term is from January 1 – December 31 2024.
AMYLOIDOSIS FOUNDATIONGrant Agreement • April 19th, 2022
Contract Type FiledApril 19th, 2022The primary purpose of The Amyloidosis Foundation (the “AF”) in funding scientifically meritorious research is to advance its mission to eradicate Systemic Amyloidosis as a life threatening disease. The policies are provided to assist applicants and grantees in understanding the terms and conditions that apply to each Grant. The full terms and conditions applicable to each Grant are set forth in this Grant Agreement, which incorporates these policies. By accepting a AF grant or fellowship, the Sponsoring Institution agrees to the terms and conditions of this Policy and accepts full responsibility for the conduct of the investigation and for the acts of the investigator; project personnel, compensated in full or in part with funds awarded by the AF, are employees of the Sponsoring Institution; they are not AF employees. Grant term is from January 1 – December 31 2023.